Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV
Open Access
- 15 January 2024
- journal article
- research article
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 6 (1) , 74-91
Abstract
Monoclonal antibodies have emerged as key therapeutics. In particular, nanobodies, small, single-domain antibodies that are naturally expressed in camelids, are rapidly gaining momentum following the approval of the first nanobody drug in 2019. Nonetheless, the development of these biologics as therapeutics remains a challenge. Despite the availability of established in vitro directed-evolution technologies that are relatively fast and cheap to deploy, the gold standard for generating therapeutic antibodies remains discovery from animal immunization or patients. Immune-system-derived antibodies tend to have favourable properties in vivo, including long half-life, low reactivity with self-antigens and low toxicity. Here we present AbNatiV, a deep learning tool for assessing the nativeness of antibodies and nanobodies, that is, their likelihood of belonging to the distribution of immune-system-derived human antibodies or camelid nanobodies. AbNatiV is a multipurpose tool that accurately predicts the nativeness of Fv sequences from any source, including synthetic libraries and computational design. It provides an interpretable score that predicts the likelihood of immunogenicity, and a residue-level profile that can guide the engineering of antibodies and nanobodies indistinguishable from immune-system-derived ones. We further introduce an automated humanization pipeline, which we applied to two nanobodies. Laboratory experiments show that AbNatiV-humanized nanobodies retain binding and stability at par or better than their wild type, unlike nanobodies that are humanized using conventional structural and residue-frequency analysis. We make AbNatiV available as downloadable software and as a webserver.Keywords
Funding Information
- Royal Society (URF\R1\201461)
- RCUK | Engineering and Physical Sciences Research Council (EP/X024733/1, EP/X024733/1)
- Isaac Newton Trust (RG89305)
This publication has 80 references indexed in Scilit:
- Maximum Allowed Solvent Accessibilites of Residues in ProteinsPLOS ONE, 2013
- Structure of an early native‐like intermediate of β2‐microglobulin amyloidogenesisProtein Science, 2013
- Monoclonal antibody humanness score and its applicationsBMC Biotechnology, 2013
- Nanobodies: Natural Single-Domain AntibodiesAnnual Review of Biochemistry, 2013
- Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic β2-microglobulin variantProceedings of the National Academy of Sciences, 2011
- Rapid cloning of high-affinity human monoclonal antibodies against influenza virusNature, 2008
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusNature Medicine, 2004
- Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis ToolJournal of Molecular Biology, 2001
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990
- Environment and exposure to solvent of protein atoms. Lysozyme and insulinJournal of Molecular Biology, 1973